Eisai, Biogen Tout BAN2401’s Clinical Effect Regardless of APOE4 Mutation

Eisai and its partner Biogen defended their controversial data for BAN2401 with subgroup analysis results presented at an Alzheimer’s disease (AD) conference in Spain, touting that the investigational drug suggested clinical effects both in carriers and non-carriers of an APOE4...read more